SCHEMBL13701425

SCHEMBL13701425

CCCOc1ccccc1C(=O)CCc1coc(-c2ccc(OC)c(OC)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCLAT1 Q6UWP7 2/20 0.40
FPR2 P25090 4/20 0.39
CTNNB1 P35222 2/20 0.39
WNT3A P56704 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
CYP2C9 P11712 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 3/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34465316 0.95 SMN1; SMN2 (0.41) LCLAT1FPR2CTNNB1WNT3ANPC1
SCHEMBL4279400 0.95 SMN1; SMN2 (0.41) LCLAT1FPR2CTNNB1WNT3ANPC1
SCHEMBL4275745 0.95 SMN1; SMN2 (0.41) LCLAT1FPR2CTNNB1WNT3ANPC1
SCHEMBL4271262 0.93 LCLAT1 (0.39) LCLAT1FPR2CTNNB1WNT3ASMN1; SMN2
SCHEMBL4280709 0.93 LCLAT1 (0.39) LCLAT1CTNNB1WNT3ANPC1RAB9A
SCHEMBL13701424 0.92 SMN1; SMN2 (0.45) CTNNB1WNT3ANPSR1SMN1; SMN2MAPT
SCHEMBL4277682 0.92 PARP1 (0.44) LCLAT1FPR2CTNNB1WNT3ANPC1
SCHEMBL4278480 0.92 PPARG (0.40) LCLAT1FPR2PDE4APDE4BPDE4C
SCHEMBL4275005 0.92 KDM4E (0.41) LCLAT1FPR2CTNNB1WNT3ANPC1
SCHEMBL4275157 0.92 LCLAT1 (0.38) LCLAT1FPR2SMN1; SMN2LMNAPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885FPR2 2089/4885CTNNB1 1636/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A LCLAT1 2111/4885FPR2 2089/4885CTNNB1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.